BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
BeyondSpring (NASDAQ: BYSI) will release its financial results for the quarter and year ending December 31, 2021, on April 14, 2022. The company will hold a conference call at 8:00 am ET to discuss these results and provide a corporate update. BeyondSpring focuses on innovative cancer therapies, particularly its lead asset, plinabulin, which has shown positive Phase 3 data for preventing chemotherapy-induced neutropenia (CIN) and improving overall survival in NSCLC patients. The company is also developing several pre-clinical immuno-oncology assets.
- Positive Phase 3 data for plinabulin in preventing CIN.
- Plinabulin combination with docetaxel met primary endpoint in NSCLC.
- None.
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:00 am Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, April 14 |
| Time: | 8:00 am Eastern Time |
| Toll Free: | 877-451-6152 |
| International: | 201-389-0879 |
| Conference ID: | 13728822 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1542381&tp_key=4941bdf92a |
About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset, plinabulin, is being developed as a “pipeline in a drug” in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). The plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd line NSCLC (EGFR wild type). Additionally, plinabulin is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring’s pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com
FAQ
When will BeyondSpring report its financial results for Q4 2021?
What time is the BeyondSpring conference call scheduled for?
What are the key developments related to plinabulin?
